טוען...
RGC-32 as a potential biomarker of relapse and response to treatment with glatiramer acetate in multiple sclerosis
Currently there is critical need for the identification of reliable biomarkers to help guide clinical management of multiple sclerosis (MS) patients. We investigated the combined roles of Response Gene to Complement 32 (RGC-32), FasL, CDC2, AKT, and IL-21 as possible biomarkers of relapse and respon...
שמור ב:
| הוצא לאור ב: | Exp Mol Pathol |
|---|---|
| Main Authors: | , , , , , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
2015
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6594183/ https://ncbi.nlm.nih.gov/pubmed/26407760 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.yexmp.2015.09.007 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|